Business
Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025
~ Pain Management, RE-Invented: A New Era for Analgesia ~ SAN DIEGO, CA / ACCESS Newswire / June 11, 2025 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions ...
About this update from Ensysce Biosciences, Inc.
[{"type":"text","content":"~ Pain Management, RE-Invented: A New Era for Analgesia ~","length":57,"tagName":"p"},{"type":"text","content":"SAN DIEGO, CA / ACCESS Newswire / June 11, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for abuse and overdose, today announced a world-class panel to discuss the current state of pain therapy at their planned scientific symposium to be held during PAINWeek 2025.","length":439,"tagName":"p"},{"type":"text","content":"PAINWeek is the largest pain conference in the world where experts meet to share knowledge to enhance patient care. The Ensysce-sponsored symposium ‘Pain Management, RE-Invented: A New Era for Analgesia' will take place in Las Vegas on September 3rd, 2025. Three world-renowned experts will discuss a range of topics to help practitioners achieve optimal results when treating severe pain. The confirmed speakers for the Ensysce symposium are:","length":447,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Dr. Jeff Gudin, University of Miami Pain Center","length":47,"tagName":"p"}]},{"val":[{"type":"text","content":"Dr. Todd Bertoch, Chief Medical Officer, Pain Research at CenExel JBR","length":69,"tagName":"p"}]},{"val":[{"type":"text","content":"Dr. William Schmidt, Chief Medical Officer, Ensysce Biosciences","length":63,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":179,"olType":false},{"type":"text","content":"Together, these experts will explore the clinical challenges of today's pain landscape, new approaches to therapy, and the promise of Ensysce's breakthrough TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) technologies - novel solutions designed to curb opioid misuse, abuse and overdose without sacrificing pain relief.","length":362,"tagName":"p"},{"type":"text","content":"Dr. Lynn Kirkpatrick, Ensysce CEO, said, "I am pleased to return to PAINWeek and immensely proud to have these outstanding experts lead the discussion around the state of treating both acute and chronic pain today in a time of shifting attitudes around analgesia. My team appreciates all the practitioners in the field that gather for this annual meeting and who do valuable...